vice president of programs, public affairs, and research at Lung Health Foundation.

Safeguards in New Lung Cancer Risk Calculator, With Jessica Moffatt, PhD

Safeguards were a central consideration in the design of the Lung Health Foundation’s online 

risk calculator, particularly given the potential for patients, or even clinicians, to overinterpret a numerical risk estimate.

In an interview with HCPLive, Jessica Moffatt, PhD, vice president of programs, public affairs, and research at Lung Health Foundation, emphasized that the tool uses clear, plain language throughout and includes explicit guidance on next steps. At multiple points in the user journey, the call to action directs individuals to speak with a primary care provider or contact their provincial screening program. The calculator is framed as a supplemental resource.

“All patients can benefit from this,” Moffatt said. “It's really meant to be user-friendly across all patient populations, but it's especially important for patients who may not have a primary care provider. In many lung cancer screening jurisdictions, you can self-refer for a risk assessment. You don't necessarily need that primary care referral, and so for those patients who don't have a primary care provider, this also is a very useful tool for them to help [them] understand if they may be eligible for screening.”

The analysis showed that the calculator could generate a 6-year lung cancer risk estimate in 2 – 3 minutes with only 10 questions. A greater calculated risk does not indicate the presence of lung cancer, and a lower score does not eliminate risk. That distinction is reinforced within the interface to reduce the likelihood that patients equate risk estimation with diagnosis.

Moffatt emphasized that clinicians should not treat this patient-generated score as a definitive eligibility determination. The only official risk assessment is the one conducted within an organized screening program. Clinicians are encouraged to use the estimate to support shared decision-making and referral considerations, not to substitute for formal program-based evaluation.

Beyond mitigating misinterpretation, investigators hope the calculator addresses known barriers to screening. By allowing individuals to privately explore their risk, the tool may help reduce stigma associated with smoking-related disease. It may also prompt more primary care providers to consider lung cancer screening when appropriate.

Moffatt acknowledged that risk models must evolve alongside the evidence base. The current framework primarily reflects heavy smoking history, but rising lung cancer incidence among never-smokers may necessitate future updates. As validated models change, organized screening programs would be expected to adapt accordingly.

For now, Lung Health Foundation positions the calculator as an evidence-informed entry point: designed to clarify, not replace, clinical judgment.

“This is one of the first repackagings of a very cumbersome tool into something that's user-friendly,” Moffatt said. “We would encourage folks to definitely check it out on lunghealth.ca where you can find more information about the risk calculator. It really is meant for anyone interested in understanding their risk profile.”

‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point. GlobeNewswire. Published on February 4, 2026. Accessed on February 12, 2026. 

https://finance.yahoo.com/news/think-mortgage-calculator-lung-cancer-123000493.html?guccounter=1&guce_referrer=aHR0cHM6Ly9zdGF0aWNzLnRlYW1zLmNkbi5vZmZpY2UubmV0Lw&guce_referrer_sig=AQAAANFnUl3Oz4FMn8kNg43vqehf_7SF1nUmh0k1LLaCpbMdC9_T-6vswljrh6fwLmRxxEGMwz-0dnFQjGKKfqJJWi0oQETyZDsfkBeYGnzfUqTpyxdDpQumjFy3NQ7FXywWocCd8t8GXlRUV3iH2g3ONrsSgg6yIeNYhnHt2F9RSZuO

Moffatt J. HCPLive. Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD. Published on February 12, 2026. Accessed on February 13, 2026. 

https://www.hcplive.com/view/tool-predicts-6-year-risk-lung-cancer-risk-minutes-jessica-moffatt-phd

Videos

Developers emphasize plain language, explicit next steps, and clear limits to ensure the PLCOm2012-based tool supports, rather than replaces, formal lung cancer screening.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lung Cancer

Mark Kaufmann, MD, is a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City.

 meeting by Mark Kaufmann, MD, a clinical professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, featured a session titled ‘How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.’

Kaufmann spoke in an on-site interview with 

 regarding this session and some of its biggest highlights, going in depth regarding tips for dermatology clinicians improving billing effectiveness and other helpful strategies related to ICD-10 codes.

 In this segment of his interview, Kaufmann spoke about tips for clinicians and about the use of artificial intelligence (AI) scribes.

“ICD-10s now may be getting us into some trouble, because companies are starting to down-code our claims and they're using the ICD-10s,” Kaufmann explained. “So they're basically saying, ‘You may think that that diagnosis deserves a level four code, but we're going to tell you it's only going to be a level three’...It's a very difficult thing to pick up sometimes, because it's easy to tell when someone tells you that they're not paying you for something, you get a zero on your explanation of benefit. But when someone's paying you less than you're billing for, that's more difficult to pick up.”

It is therefore important, Kaufmann put forth, to examine one’s explanation-of-benefits (EOBs). The lack of adequate payment may not be as visible. Later, Kaufmann was asked about the future of dermatology and any important information for clinicians in the coming months and years. Kaufmann advised clinicians to consider alternative revenue streams and also highlighted the value of AI scribes.

“You need to know which types of diagnoses and which types of words will trigger a change,” Kaufmann said. “And that's where the AI scribe comes in, where it actually knows which words change the complexity of the diagnosis.”

The quotes in this interview summary were edited for the purposes of clarity.

Kaufmann previously disclosed serving as a consultant for companies such as Apogee Therapeutics, Avita Medical, and Biofrontera, and he has held a position on the medical advisory board for Modernizing Medicine, Inc.

Kaufmann M, Siegel D. How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Kaufmann M. Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD. HCPLive. February 12, 2026. Accessed February 13, 2026. 

https://www.hcplive.com/view/strategies-maximizing-billing-effectiveness-clinicians-mark-kaufmann-md

This segment of an interview from Maui Derm Hawaii, featuring Mark Kaufmann, MD, highlights key advice on AI scribe use and billing effectiveness in dermatology practices.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Discussing AI Scribes and Improving Billing Practices in Dermatology, With Mark Kaufmann, MD

Zobair Younossi, MD, MPH, is chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System.

From Validation to Implementation: Scaling NITs in MASLD Care, With Zobair Younossi, MD, MPH

As the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to climb in parallel with obesity and type 2 diabetes, clinicians face a pressing question regarding how at-risk patients should be identified and managed in routine practice.

Although noninvasive tests (NITs) have been validated for fibrosis risk stratification and are increasingly incorporated into society guidelines, their adoption remains inconsistent across care settings. At the same time, therapeutic options for metabolic dysfunction-associated steatohepatitis (MASH) are expanding, raising the stakes for early and accurate case finding. Against this backdrop, the conversation is shifting from whether to use noninvasive testing to how quickly and broadly it should be implemented and what barriers must be addressed to make risk-based MASLD care a standard part of clinical workflows.

, Zobair Younossi, MD, MPH, professor and chairman of the Global NASH Council, makes a clear and urgent case that the time to implement NIT-based risk stratification for MASLD is now.

Check out part 1 of the interview with Younossi 

While no test is perfect, he argues the data are sufficiently strong to support widespread adoption across clinical settings, most recently from his trio of sequentially published papers on how NITs perform across regions, how well they predict liver-related outcomes compared with biopsy, and how their accuracy varies in key subgroups.

“I think we should adopt it now,” Younossi said. “The data is not perfect, but it's pretty good, and these tests should be adopted in every clinical practice.”

He stresses that waiting for a flawless diagnostic tool risks further delay in addressing a disease that is already a leading cause of liver transplantation and hepatocellular carcinoma in the United States. Instead, he calls for implementation across primary care, endocrinology, diabetology, gastroenterology, and hepatology. MASLD, he notes, should be viewed similarly to other diabetes-related complications. Just as clinicians routinely screen for retinopathy and nephropathy, liver risk assessment should become standard practice in patients with metabolic disease.

At the same time, he notes that important gaps remain. While current NITs are highly effective for identifying advanced fibrosis, they are less precise in detecting patients with earlier yet clinically meaningful stage 2 (F2) fibrosis. Younossi points to ongoing work leveraging large datasets, machine learning, and artificial intelligence to develop more refined combination algorithms and calls for a paradigm shift in drug development. With NITs now guiding real-world clinical decisions, he argues that clinical trials should move away from mandatory biopsy-based enrollment and instead transition toward NIT-based designs that better reflect contemporary practice.

He also notes that barriers to adoption extend beyond diagnostics, with awareness remaining a major challenge requiring education at multiple levels: provider, public health policy, and global health leadership.

“I think in the next 5 years, you'll see additional drugs and more help for patients with progressive MASH,” Younossi said. “In that context, I think it’s going to be very important that we identify those patients, we develop care pathways where we connect these patients who are at risk with a care provider that will not only give them advice and properly manage their cardiometabolic risks with diet, exercise, and also the medication that we have available for diabetes and hypertension, but also, if they are candidates for treatment with MASH drugs, that they're offered. We'll have more drugs in the pipeline, and hopefully we'll have patients ready by then.”

Editors’ Note: Younossi reports relevant disclosures with Intercept, Cymabay, Boehringer Ingelheim, Ipsen, BMS, GSK, Novo Nordisk, Siemens, Madridgal, Merck, Aligos, Akero, Sanofi and Abbott.

Younossi ZM, de Avila L, Petta S, et al. Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study. 

. Published online January 28, 2026. doi:10.1016/j.cgh.2026.01.016

Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Rudolf Valenta, of the Medical University of Vienna

Seasonal Allergen Exposure Recalls IgE Plasmablasts in Birch Allergy, With Rudolf Valenta

A new longitudinal study found that IgE⁺ plasmablasts are the primary cellular drivers of seasonal IgE increases in birch pollen allergy.

, of the Medical University of Vienna, about the study’s implications. He highlighted the significance of increased seasonal IgE without a corresponding IgG response.

“Look, this is a very hot debate,” Valenta said. “There [are], I would say, two different schools here. There's one school that comes from mouse immunology. In the mouse, there is something like a sequential car switch, so if you start to sensitize a mouse to develop IgG antibodies, it's usually done by injection or by high doses of inhalation, the mouse develops IG and IgG antibodies against the same epitopes. In the human, this is not the case, because if the human would produce the IgG antibodies against the same epitopes as IgE, the person would be protected and not be allergic. The story is that [people] …push this idea of the sequential car switch in, I dare to say, very important journals here, and it's true for the mouse. The thing is, [when we] undertake our investigations in patients and in the patient, it's different.”

In this study, patients have no induction of IgG antibodies, nor are these antibodies against the IgG epitopes. However, this is the case of IgE antibodies.

If seasonal exposure triggered IgG against the same epitopes, it would act like natural immunotherapy, generating blocking IgG antibodies. Except, this does not happen; people become more sensitized after the season.

“So that's one of the reasons why we put a little bit of emphasis on this,” Valenta continued. “It’s a major observation.”

Bet v 1–specific IgE levels increased significantly during peak pollen season compared with pre-season (TP1 vs TP3; 

 < .01) and declined after the season ended (TP3 vs TP5;

 < .05). In contrast, bet v 1–specific IgG1 and IgG4 levels did not show significant seasonal changes.

Flow cytometry demonstrated a significant rise in circulating IgE⁺ plasmablasts (CD19⁺CD27⁺CD38⁺CD20low) during pollen exposure. Epitope mapping showed that the seasonal IgE boost targeted pre-existing conformational epitopes of Bet v 1, rather than generating new specificities. Functionally, this plasmablast-derived IgE reloaded effector cells, restoring allergen-specific basophil activation that had waned outside the season.

Valenta said that omalizumab could have upstream effects beyond neutralizing circulating IgE. Because the antibody does not bind IgE already attached to high- or low-affinity receptors, it may selectively target IgE-expressing B-lineage cells. This raises the possibility of weakening IgE memory responses, although clinical studies are needed.

“What we actually proposing is that this antibody could be used to eliminate such cells, and that could be a very strong bullet in killing IG responses in patients,” Valenta said. “It's different from the idea of the Regeneron [company], who want to prevent the gas switch, because this is something we think is not so important [for] the patients. We also say it's not the plasma cells, because they have a kind of continuous production that fades away, so we have in the middle what we think is a crucial cell that we can target.”

Byazrova, M., Litovkina, A., Eckl-Dorna, J. 

 Seasonal allergen exposure recalls IgE+ plasmablasts to reload allergic effector cells. 

https://doi.org/10.1007/s44466-025-00018-w

Valenta discusses how seasonal allergen exposure selectively boosts IgE production through plasmablast recall, without a coordinated IgG response.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Seasonal Allergy

Ruchika Goel, MD, is a professor and associate vice chair of research at SIU School of Medicine.

in neonates and older children, reduced platelet increment (PI) did not lead to worse clinical outcomes, suggesting that this marker does not precipitate an increased, automatic need for transfusion.

In addition to these findings, study investigators draw attention to data that 3.6% of neonates and older children had ≥1 platelet transfusion, highlighting the importance of critically assessing transfusion practices in this population.

“From a clinical perspective, we need to assess our adherence to the platelet transfusion guidelines and also the marker, post-transfusion platelet increment. It may be an imperfect surrogate for looking at patient-centred outcomes,” said Ruchika Goel, MD, professor and associate vice chair of research at SIU School of Medicine, in an interview with 

 “For example, if you're giving platelets as prophylaxis to prevent bleeding or as therapy to treat bleeding. From a clinician's lens, this study points to judging your effectiveness by the clinical context and the overall bleeding risk, and not just by the platelet count increment or the bump alone.”

Transfusions are the only available treatment to raise platelet counts in thrombocytopenic infants, aiming to stop or prevent bleeding. While they can prevent bleeding, platelet transfusions are associated with increased inflammation and can sometimes increase mortality or morbidity in neonates.

Goel and colleagues defined a platelet transfusion event as the issue of a platelet product by the transfusion service within the encounter start and end times. They calculated transfusion incidence as a binomial proportion of encounters during which ≥1 platelet product was issued, for the total population and by patient sex, age, and self-reported race and ethnicity.

The cohort study involved data on 249,340 inpatient encounters from 7 blood centers and 22 hospitals collected by the ​​Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric. The included patients were 0 to < 18 years of age. Investigators defined neonates as those < 28 days of age, and patients were otherwise considered older children.

Goel and colleagues observed ≥1 platelet transfusion in 3.6% of the study population (n = 8874). Of these, 3.3% were female, 3.7% were male, and the average age was 2.5 years, with a median weight of 1.6 kg.

Upon analysis of 40,779 platelet transfusion episodes, the median number per patient encounter was 2. 

In neonates, 32.2% of platelet transfusions were given at pretransfusion platelet counts < 25 × 103/µL, the remaining were given at increased pretransfusion platelet counts, including 38.5% at >25-50 × 103/µL, 19.6% at >50-100 × 103/µL, and 9.7% at >100 × 103/µL. The median transfusion dose was 14.9 mL/kg.

In older children, investigators analysed 26,570 transfusion events, with 19.0% of platelet transfusions given at pretransfusion platelet counts < 10 × 103/µL and the remaining were at higher pretransfusion platelet counts, including 3.0% at >100 × 103/µL. The median transfusion dose was 9.6 mL/kg.

Overall, investigators saw significantly elevated pretransfusion platelet count in neonates (34 × 103/µL [20-54 × 103/µL] compared with older patients (22 × 103/µL [11-40 × 103/µL]; 

 < .001). Post-transfusion PI was highest for pretransfusion platelet counts < 25 × 103/µL and decreased for higher counts, becoming negative (median, −25 × 103/µL for counts > 100 × 103/µL. Similarly, among infants and older children, PIs were highest for counts <10 × 103/µL and decreased for higher counts, becoming negative (median, −22 × 103/µL) for counts > 100 × 103/µL.

Platelet components stored in PAS had reduced odds of posttransfusion PI higher than 15 × 103/µL compared with platelet components not stored in PAS (adjusted Odds Ratio [AOR], 0.32 [95% CI, 0.27-0.37). Platelet storage > 3 days) was associated with decreased odds of PI > 15 × 103/µL (AOR, 0.67; 95% CI, 0.58-0.76 to 0.82; 95% CI, 0.76-0.88). Pathogen-reduced platelet components were associated with lower odds of achieving an increment higher than 15 × 103/µL (AOR, 0.82 [95% CI, 0.73-0.92]).

Assessing donor factors, investigators observed male sex was associated with reduced odds (AOR, 0.92; 95% CI, 0.86-0.98) of posttransfusion PI >15 × 103/µL per transfusion event. Additionally, donor age of ≥ 40 years compared with donor age 25 to < 40 years was independently associated with reduced odds of a PI >15 × 103/µL platelet increment (AOR, 0.79; 95% CI, 0.72-0.86).

In multivariable analysis, no donor or platelet characteristics were associated with a difference in risk of hospital discharge after 7 days (Adjusted Rates Ratio [ARR], 1.03; 95% Confidence Interval [CI], 0.89-1.20] for PR). Further, the rate of mortality was unchanged among platelet characteristics after an offset for the hospital length of stay of the encounter (ARR, 0.66 [95% CI, 0.42-1.04] for PR).

“A lower platelet increment should not automatically be used as a marker to lead to higher need for transfusion or, hence, an increased transfusion burden, because we are not necessarily seeing these to be related to clinical outcomes.”

References
Goel R, Karam O, Warden DE, et al. Platelet Transfusion Practices and Outcomes in Neonates and Children. 

https://doi.org/10.1001/jamanetworkopen.2025.54531

Neonatal Platelet Transfusions See Increased Inflammation, Not Reduced Bleeding. Hematology Advisor. Published November 25, 2025. Accessed February 12, 2026. 

https://www.hematologyadvisor.com/news/neonatal-platelet-transfusion-inflammation-bleeding-treatment-risk/

Podcasts

Low post-transfusion platelet increments did not predict mortality or length of stay in pediatric patients.

Hematology

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

When Platelet Increments Matter, With Ruchika Goel, MD

Jeffrey Downey, PhD, is a postdoctoral student at the Swirski laboratory at Icahn School of Medicine at Mount Sinai.

Downey discusses the recent discovery of influenza’s interaction with the interferon 1 pathway, as well as a hypothetical method for preventing it.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Influenza

The HCPLive influenza page is a resource for medical news and expert insights on the flu. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for influenza, and more.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

Interferon 1 Responsible for Causing Cardiac Events During Influenza Infection, With Jeffrey Downey, PhD

The free, user-friendly calculator provides a 6-year lung cancer risk estimate to help patients and clinicians assess screening eligibility.


Tool Predicts a 6-Year-Risk Lung Cancer Risk in Minutes, With Jessica Moffatt, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Articles

Survey findings highlight abdominal and bowel symptom control, affordability, and formulary or insurance coverage as factors driving perceptions and prescribing patterns of PERT.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Real-World Prescribing Patterns of PERT in Exocrine Pancreatic Insufficiency

Mark Kaufmann, MD, speaks on maximizing your billing effectiveness in the era of dwindling reimbursements and ICD-10.

Strategies on Maximizing Billing Effectiveness for Clinicians, With Mark Kaufmann, MD

Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.

Diagnostic Performance of NITs Across MASLD Subgroups, With Zobair Younossi, MD, MPH

Frank Gonzalez is an attending physician at Children’s Hospital Los Angeles and an assistant professor of clinical pediatrics at Keck School of Medicine of USC.

Gonzalez explains how new findings in weather-related emergency department visits and pain in pediatric sickle cell disease can guide clinicians. 


Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Managing Climate Change-Induced Sickle Cell Pain Crises With Frank Gonzalez, MD

David Rizik, MD, is an interventional cardiologist at Banner University Health.

Rizik and Morris discuss the Heartflow PCI Navigator, which analyzes CT scans to generate 3D models of calcium blockages ahead of procedures.

Banner Health Debuts AI 3D Vascular Modeling Device, With David Rizik, MD, and Michael Morris, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

In this Q&A, investigators Maria Byazrova and Rudolf Valenta discuss findings on plasmablast's role in seasonal IgE surge when it comes to birch allergy.

Seasonal IgE Surge in Birch Allergy Driven by IgE⁺ Plasmablasts: Q&A With Investigators

The data represent the highest and most significant improvement in AHV and the first statistically significant improvement in body proportionality in achondroplasia.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial

Ashfaq Marghoob, MD, is a dermatologist specializing in the diagnosis and treatment of cancers of the skin and the director of the Memorial Sloan-Kettering regional skin cancer clinic.

In this Q&A segment of his interview, Marghoob speaks on-site at Maui Derm on tips related to dermoscopy and skin cancer detection.

Latest News

Safeguards in New Lung Cancer Risk Calculator, With Jessica Moffatt, PhD

Discussing AI Scribes and Improving Billing Practices in Dermatology, With Mark Kaufmann, MD

From Validation to Implementation: Scaling NITs in MASLD Care, With Zobair Younossi, MD, MPH

Seasonal Allergen Exposure Recalls IgE Plasmablasts in Birch Allergy, With Rudolf Valenta

When Platelet Increments Matter, With Ruchika Goel, MD